QuidelOrtho Executive and Leadership Team

Noriaki Kawana, the President (Japan) at QuidelOrtho, leads the company's strategic initiatives and operational execution within the Japanese market. Kawana directs the sales, marketing, and distribution efforts for QuidelOrtho's diagnostic equipment, including solutions for clinical chemistry, immunodiagnostics, molecular, and rapid antigen testing, tailored to the specific needs of Japanese healthcare providers. This regional leadership role is crucial for expanding QuidelOrtho's presence and impact in one of the world's key healthcare markets. By fostering strong relationships with local partners and understanding regional market dynamics, Noriaki Kawana drives revenue growth and market share. The focus remains on delivering innovative diagnostic technologies that improve patient care and support the Japanese healthcare system's evolving demands, ensuring QuidelOrtho's sustained success in the region.

Jonathan Siegrist, the Executive VP, Research Development & Chief Technology Officer at QuidelOrtho, directs the company's technological vision and innovation pipeline. Siegrist oversees all research and development initiatives, ensuring the creation of cutting-edge diagnostic equipment for clinical chemistry, immunodiagnostics, molecular, and rapid antigen testing. This leadership role involves guiding cross-functional teams to translate scientific discoveries into market-ready products that enhance clinical decision-making. By fostering a culture of continuous improvement, Jonathan Siegrist drives the technological advancements necessary for QuidelOrtho to maintain its competitive edge in the medical technology sector. The strategic development of new platforms and the enhancement of existing product lines fall under Siegrist's purview, directly impacting the company's ability to serve global healthcare needs and expand its market presence in transfusion medicine and beyond.

Philip McLellan, the Chief Operations Officer at QuidelOrtho, manages the company's global operational infrastructure and supply chain. McLellan directs the manufacturing processes for QuidelOrtho's diverse product lines, including equipment for clinical chemistry, immunodiagnostics, molecular, and rapid antigen testing. This critical role ensures efficient production, quality control, and timely delivery of essential medical technologies across North America and other key markets. By optimizing manufacturing workflows and logistics, Philip McLellan supports the company's mission to provide reliable diagnostic solutions. The operational oversight extends to managing production facilities and ensuring compliance with stringent industry regulations, directly contributing to QuidelOrtho's market impact and its ability to meet the demands of healthcare providers worldwide. McLellan's leadership ensures the seamless execution of production strategies, underpinning the company's growth.

Nathaniel Sisitsky, the Chief Legal Officer at QuidelOrtho, provides strategic legal counsel and oversees all legal affairs for the organization. Sisitsky manages corporate governance, intellectual property, regulatory compliance, and litigation matters, ensuring QuidelOrtho operates within legal frameworks across its global operations. This executive function is vital for safeguarding the company's assets and reputation as it manufactures equipment for clinical chemistry, immunodiagnostics, molecular, and rapid antigen testing. By navigating complex legal landscapes, Nathaniel Sisitsky supports the company's expansion and product development initiatives. The legal department under Sisitsky's direction ensures adherence to international standards and mitigates risks associated with the medical technology industry, thereby facilitating QuidelOrtho's continued success and market leadership in transfusion medicine and diagnostics.